Global Diabetic Therapeutic Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: Disease overview: Diabetes

• Diagnosis of diabetes
• Complications associated with high blood glucose levels

PART 06: Pipeline portfolio

• Pipeline for new drug application (NDA) filings
• Pipeline for Phase III molecules
• Pipeline for Phase II molecules
• Pipeline for Phase I molecules
• Pipeline for pre-clinical stage molecules
• Pipeline for discovery stage molecules

PART 07: Market landscape

• Market overview
• Five forces analysis

PART 08: Overview of marketed products

• Synopsis of key diabetic drugs
• Marketed product profiles

PART 09: Market segmentation by type of disease

• Global type 1 diabetes market
• Global type 2 diabetes market
• Global gestational diabetes market

PART 10: Market segmentation by drug class

• Insulin therapies
• Non-insulin therapies

PART 11: Geographical segmentation

• Diabetic therapeutic market in Americas
• Diabetic therapeutic market in US
• Diabetic therapeutic market in EMEA
• Diabetic therapeutic market in Europe
• Diabetic therapeutic market in Germany
• Diabetic therapeutic market in UK
• Diabetic therapeutic market in France
• Diabetic therapeutic market in Italy
• Diabetic therapeutic market in Spain
• Diabetic therapeutic market in APAC
• Diabetic therapeutic market in China
• Diabetic therapeutic market in India

PART 12: Market drivers4

• Change in patient preference
• Focus on self-management of diabetes
• The strong potential of biologics
• Unmet medical needs and scope for DMDs

PART 13: Impact of drivers

PART 14: Market challenges

• Complex storage conditions and distribution policies for insulin
• Unpredictable outcomes on human due to lack of predictable animal models
• Gap in nation-level diabetes management plans
• Rising concerns in the scientific community

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Focus on oral insulin therapies
• Growing technological integration fueling the market growth
• Focus on regenerative medicines
• Strong and diversified pipeline portfolio

PART 17: Vendor landscape8

• Competitive scenario
• Market analysis 2016
• Upcoming vendors for oral insulin therapies
• Oramed Pharmaceuticals
• Generex Biotechnology
• Other prominent vendors

PART 18: Key vendor analysis

• Novo Nordisk
• Sanofi
• Merck
• Eli Lilly
• AstraZeneca

PART 19: Appendix

• List of abbreviations

PART 20: Explore Technavio